American Bar Association Webinar – Sanofi/Maze: An A-maze-ing Expansion of the Nascent Competition Doctrine?
Event summary
Sanofi recently abandoned its proposal to license Maze’s developmental drug to treat Pompe disease in the face of the Federal Trade Commission’s decision to seek a preliminary injunction to block the deal. This move highlights the agency’s commitment to closely scrutinize nascent competition in life sciences and pharma deals. The panel discussed the implications of the FTC’s challenge.
Megan Browdie, Cooley partner and vice chair of the ABA Antitrust Law Section Health Care and Pharmaceuticals Committee, moderated the panel.
For more information, please email Yena Lee.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.